Replies to post #156500 on Biotech Values

[jq1234]

Portola: PTLA file $115m IPO

Form S1:

http://archive.fast-edgar.com/20130412/Aabt5znp7fXW-pQJ-mZd-q-eGc5XZ/

From biz journal:

http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/04/portola-pharmaceuticals-ipo-ptla.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+BiotechsfRssFeed+%28BiotechSF%29

[DewDiligence]

PTLA inks phase-3 clinical collaboration with Bayer/JNJ for Andexanet Alfa (f/k/a PRT4445) as an antidote to Xarelto:

http://finance.yahoo.com/news/portola-pharmaceuticals-enters-clinical-collaboration-130000148.html

This PR (which was issued on 2/3/14) extends the collaboration these companies already had to complete a phase-2 trial (#msg-84232022). As was the case with the phase-2 collaboration, financial terms were not disclosed.